Key Takeaways:
Valion Bio Inc. (Nasdaq: VBIO) has secured up to $7 million in U.S. government funding to advance its lead drug candidate for Acute Radiation Syndrome (ARS), significantly de-risking the path to approval for a countermeasure targeting an unmet medical need.
The agreement with the National Institute of Allergy and Infectious Diseases (NIAID) provides not just capital but also critical regulatory guidance. "When NIAID provides both the capital and the regulatory institutional knowledge to advance a program, that is a materially different risk profile than a company-sponsored study," said Michael K. Handley, Chief Executive Officer of Valion Bio.
Under the non-clinical evaluation agreement, NIAID will fully fund the in vivo studies required for Valion's Biologics License Application (BLA) for the drug, Entolimod. The studies will be conducted at the Armed Forces Radiobiology Research Institute (AFRRI) using a protocol identical to one the FDA has previously accepted for an ARS countermeasure, a move the company says meaningfully lowers regulatory design risk.
For investors, the government backing provides a direct line of sight to a BLA submission under the FDA's Animal Rule pathway and frees up company capital. Valion Bio now plans to redirect the approximately $7 million it had budgeted for this program toward developing Entolasta, its second-generation molecule, effectively creating two parallel-funded development tracks.
The initial NIAID-funded study will evaluate Entolimod's ability to protect gastrointestinal tissue after partial-body radiation. This is a critical distinction, as no currently approved or stockpiled countermeasure—such as Neupogen® (filgrastim) or Neulasta® (pegfilgrastim)—has demonstrated efficacy in preserving the GI tract, which can fail within 48 hours of exposure regardless of bone marrow function.
Entolimod works as a TLR5 agonist, a mechanism designed to protect both hematopoietic (blood-forming) and gastrointestinal tissues. This dual action could address the full lethal injury cascade from radiation, a capability not covered by existing G-CSF agents that only support hematopoietic recovery. The drug has already been administered in 42 non-human primate studies and to approximately 300 human subjects.
The NIAID funding adds to an already substantial investment in the Entolimod program, which totals over $140 million to date, including about $35.6 million in prior U.S. government funding. By taking over the BLA-enabling costs, the government is effectively accelerating Valion's pipeline.
"The capital we had planned to deploy on this program — approximately $7 million — can now be redirected toward advancing Entolasta™, our second-generation molecule, into clinical development," Handley stated. This allows the company to pursue its commercial pipeline in oncology supportive care while the government-backed ARS program advances, a strategy the CEO described as "compounding priorities." Upon favorable study outcomes, NIAID has committed to co-navigate the FDA submission process alongside Valion Bio.
This article is for informational purposes only and does not constitute investment advice.
